CancerLinQ LLC Collaborating with the International Association for the Study of Lung Cancer

Leading Global Association Will Provide CancerLinQ with Disease Specific Support from Lung Cancer Experts
May 7, 2019

CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) have announced a collaboration to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC will contribute thought leadership and subject matter expertise to CancerLinQ including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content.

CancerLinQ LLC is a wholly owned nonprofit subsidiary of ASCO that is developing and operating CancerLinQ®, a real-world, big data initiative focused on cancer patient medical information. The platform collects and analyzes real-world data from patients at practices nationwide with the goal of improving the quality of patient care and outcomes. The project also aims to deliver new insights from research and discovery.

“The real-world cancer data that CancerLinQ® collects contributes vital information to the oncology field across cancer types,” said CancerLinQ LLC Chief Executive Officer Cory Wiegert. “This collaboration allows us to work with the IASLC as we analyze CancerLinQ’s data on lung cancer, the most commonly occurring and lethal cancer worldwide.”

The IASLC has a membership of more than 6,500 lung cancer specialists in over 100 countries, who work to enhance the understanding of lung cancer among scientists, members of the medical community, and the public. This engagement with CancerLinQ furthers the IASLC’s mission to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world. 

“The strength in this collaboration between the IASLC and CancerLinQ ultimately comes in the form of earlier and better diagnoses and better outcomes for lung cancer patients,” said IASLC Chief Executive Officer Dave Mesko. “As the leading voice in the study of thoracic malignancies, the IASLC brings a multidisciplinary, multinational perspective and the expertise to identify the best application of the lung cancer data revealed from this project.”

The collaboration with the IASLC is one of many that CancerLinQ LLC has entered into with a coalition of partners and thought leaders, including government agencies, medical specialty societies, and life sciences companies. Since 2016, the American Academy of PAsAmerican College of Medical Genetics and GenomicsAmerican Society of Radiation OncologyAssociation for Molecular PathologyCancer Informatics for Cancer CentersCollege of American PathologistsDIAFood and Drug AdministrationHematology/Oncology Pharmacy AssociationNational Cancer InstituteNational Society of Genetic CounselorsOncology Nursing Society, and Society of Gynecologic Oncology have joined forces with CancerLinQ LLC. Additionally, in November 2016, AstraZeneca became a founding enterprise partner with CancerLinQ Discovery®. These relationships offer the CancerLinQ team guidance and insights that ultimately can contribute to the quality and efficiency of the cancer care delivery system.

CancerLinQ® and CancerLinQ Discovery® are projects of CancerLinQ LLC. For more information about either initiative, please go to www.CancerLinQ.org.

ASCO in Action